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Background: The safety and efﬁcacy of the Absorb (Abbott) bioresorbable
vascular scaffold (BVS) has been documented in lower-risk patient and lesion subsets
with “real-world” outcome data being scarce. Here we report the experience gathered
with BVS primarily in daily practice at a high-volume Dutch center.
Methods: Between July 2009 - April 2014, a total of 169 patients (194 lesions)
were treated with BVS, of which the ﬁrst 36 patients were treated within the scope
of the ABSORB studies. Clinical presentation of pts. (75% male, mean age 58 yrs,
16% diabetes) was ACS in 47%. Multi-vessel disease was present in 39%. Lesion
complexity was B2/C in 59% and mean lesion length 18.2 mm. Pre-dilatation was
performed in 96% and post-dilatation in 54%. The mean scaffold length was 29
mm with 34% of cases using 2 scaffolds and 25% of cases using overlapping or
adjacent scaffolds. OCT or IVUS was used in 42%. Registry data was collected
prospectively in-hospital, at 1 and 6 months and then yearly up to 4 years. Mean
follow-up time was 298 days (range 0-1534 days) with 46% of patients having at
least 1 year of follow-up.
Results: Procedural success was 99.4% (failure to achieve stent-expansion in 1 pt.)
and device success 98.8% (failure to deliver BVS in 2 pts.). Over the entire follow-up
period, death occurred in 2.4% (2 cardiac and 2 non-cardiac), myocardial infarction
(MI) in 3.0% (total of 5 cases, 1 of peri-procedural), target lesion revascularization in
3.6 %, target vessel revascularization (TVR) in 4.2%, non-target vessel revasculari-
zation 0.6%. Deﬁnite stent thrombosis (ST) occurred in 3 pts. (1.8%) and probable ST
in 1 pt. (0.6%); all ST were early within 48 hours except one case of deﬁnite ST which
occurred at 7 months. Overall MACE (death, MI, TVR) during follow-up occurred in
8.3% of patients (n¼14).
Conclusions: This registry including patients with ACS and complex lesion charac-
teristics documents a good efﬁcacy and reasonable safety proﬁle of the BVS. Stent
thrombosis, in particular early after BVS implantation, is not infrequent and has to be
closely monitored. Randomized data is needed to deﬁne the role of BVS in daily
practice including complex patient and lesion subsets.
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Background: Bioresorbable vascular scaffolds (BVS, Abbott Vascular, Santa Clara,
California, USA) are new options for treatment of coronary stenoses. Due to a large
crossing proﬁle, the implantation procedure is more complex than for current metal
stents. Thus, a learning curve might be present. We analyzed whether there is a
relationship between the outcome of coronary PCI with BVS and speciﬁc operator
experience with this treatment modality.
Methods: 200 consecutive patients included in a multi-center all-comers registry of
coronary revascularization procedures with BVS were divided into the ﬁrst 100
(group A) vs. the second 100 individuals (group B). We compared procedural
parameters and complication rates, as well as in-hospital outcome and mid-term
follow-up results.
Results: Baseline characteristics in both groups were not signiﬁcantly different. The
number of implanted BVS was 131 (1.2 per patient) in group A versus 149 (1.4 per
patient) in group B (p¼n.s.). No differences were documented between group A and
B for median procedure time (48 vs. 51 min; p¼n.s.), mean contrast volume (195.0
 100.0 mL vs. 183.2  80.4 mL; p¼n.s.), mean ﬂuoroscopy time (13.7  8.7min
vs. 13.9  8.1min; p¼n.s.), or number of predilatations performed (1.4:  0.8 vs.
1.4  1.4; p¼n.s.). However, post dilatation (23.8% vs. 50.5%, p< 0.01) and
intravascular imaging (9% vs. 19%, p< 0.05) were used signiﬁcantly more
frequently in group B. There was no difference in the rates of severe procedure
related complications (group A: 2%; group B: 3%, p ¼n.s.), in-hospital MACE (2%
vs. 3%, p¼n.s.), or median length of hospital stay (4 days in both groups). During
follow-up (median 210 vs. 192 days, p ¼ n.s.) total rates of MACE, TVF and TVR
where signiﬁcantly higher in group A (MACE: 12% vs. 3%, p< 0.05; TVF: 9% vs.
2%, p< 0.05; TVR: 9% vs. 2%, p< 0.05). Additionally, TLR rate tended to be
higher in group A (6% vs. 2%; p¼n.s.).
Conclusions: The ﬁndings of this registry suggest that in an all-comers population
BVS implantation beneﬁts from operator experience with the device and from routine
use of post-dilatation. The use of intravascular imaging to guide implantation might be
favorable.B182 JACC Vol 64/11/Suppl B j September 13–1TCT-624
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Background: Although bioresorbable scaffolds (BRS) may have important beneﬁts,
their deployment requires more aggressive lesion preparation compared to the best
metallic DES due to different radial force and crossing proﬁle. In addition, the beneﬁts
of post dilatation (PD) have not been systematically studied, with reports of fracture if
the BRS expansion limits are exceeded by excessive PD. We sought to determine the
impact of PD on clinical outcomes in a large cohort of patients treated with the Absorb
only.
Methods: We evaluated all consecutive patients enrolled in the multicenter, single
arm ABSORB EXTEND Study through June 2013. The study allowed treatment of up
to 2 coronaries (diameter 2.0 to 3.8mm) and the use of overlapping (lesion length 
28mm). Patients with severe lesion calciﬁcation/tortuosity were excluded. Aggressive
lesion pre dilatation (balloon to artery ratio of 0.9-1.0) was mandatory and PD was left
to the operator’s discretion (if performed, non-compliant balloons up to 0.5mm larger
than the Absorb had to be used). Patients were grouped according to whether PD was
performed or not, and the one-year incidence of TLF and scaffold thrombosis were
compared.
Results: 768 patients were enrolled in the study and PD was performed in 526
(68.4%). There were no signiﬁcant differences between the PD group and no-PD
group in baseline characteristics, moderate calciﬁcation (13.7% vs.12.7%, p¼0.7) and
incidence of B2/C lesions (43.9% vs. 41.8%), as well as lesion length (12.3mm vs.
12.1mm, p¼0.6) and RVD (2.6mm for both groups, p¼0.2). Residual in-scaffold
stenosis (15.4  6.5% with PD, 14.9  6.1 without PD, p¼0.3) and the need for
bailout scaffold/stent (4.2% with PD, 4.5% without PD, p¼0.8) were also comparable.
At 1 year, there was no difference in TLF (5.4% in the PD vs. 2.6% in the non-PD
group, p¼0.13); all individual components of TLR, death, and MI were also similar.
There were no signiﬁcant differences in MACE and def/probable stent thrombosis
between the two groups.
Conclusions: These results reﬂect very similar ﬁnal angiographic and clinical results
achieved with or without post-dilatation in the treatment of low to moderately com-
plex lesions.
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Background: In order to assess the long term safety, clinical performance and the
bioabsorption process of the paclitaxel-eluting absorbable magnesium Scaffold
(DREAMS) 3-year clinical data and multi-modality imaging outcomes are reported.
Methods: Forty-six subjects were enrolled in the ﬁrst-in-man BIOSOLVE-I study in
two different cohorts with clinical follow-up at 1, 6, 12, 24 and 36 months; angio-
graphic and IVUS follow-up for cohort 1 at 6-month and for cohort 2 at 12-month. A
subgroup of patients underwent OCT and vasomotion testing. The primary endpoint is
Target Lesion Failure (TLF) at 6-month for cohort 1 and at 12-month for cohort 2. For
some patients also 18-month and 24-month imaging data are available.
Results: TLF rate at 36-month was 6.8% including 2 TLRs and 1 peri-procedural MI
occurring at the 12-month follow-up angiography; no events emerged from 12- to 36-
month. No cardiac death or scaffold thrombosis was observed. Vasoconstriction after
acetylcholine at 6-month (delta¼-10.04%; p¼0.0008 versus baseline) followed by
vasodilatation after nitroglycerine (delta¼8.69%; p< 0.0001 versus baseline) dem-
onstrates the uncaging aspect of the absorption process with no further change at the
12-month follow-up. Six-month virtual histology (VH) data showed a signiﬁcant
decrease in the dense calcium by 39.5% (p¼0.0015) remaining stable from 6- to 12-
month follow-up. This decrease is interpreted as a surrogate assessment for the bio-
absorption process of the scaffold material. Echogenicity data using the decrease in
intensity of the ultrasound signal to quantify the change in strut structure demonstrate
a continuous decrease in % hyperechogenicity over the follow-up period, with the
most pronounced changes within the ﬁrst 6 months (22 to 16% p< 0.001).7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
